22 Million in Cash for this NASDAQ insures Operating Capital into Mid 2022; FDA Review of ACER 001 Bodes well for Acer Therapeutics Inc. (NASDAQ: ACER)
– Pharmaceutical Developer of Multiple Candidates for Inborn Conditions of Metabolism and a Variety of Infectious Diseases.
– Collaboration and License Agreement with Relief Therapeutics for Worldwide Development and Product Commercialization.
– Plans for Phase 3 Clinical Trial Planned of EDSIVO(TM) for Treatment of Vascular Ehlers-Danlos Syndrome Following Type B FDA Meeting.
– Plans for NDA Submission of ACER-001 for Urea Cycle Disorders and Maple Syrup Urine Disease Following Pre-NDA Meeting with FDA.
Acer Therapeutics Inc. (NASDAQ: ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
ACER reported financial results for the second quarter ended June 30, 2021 and provided an update on the Company’s recent corporate developments.
“This quarter marks significant, meaningful progress across our entire pipeline, including the very recent submission of our NDA for ACER-001 for the treatment of UCDs,” said Chris Schelling, CEO and Founder of Acer. “As we anticipate working closely with the FDA on the review process for ACER-001, we continue to make significant progress across the rest of our pipeline, including preparation of two IND submissions targeted for Q4 of this year. These INDs are expected to support initiating a dose-ranging Phase 2a study for ACER-801 (osanetant) for the treatment of vasomotor symptoms, and a pivotal Phase 3 study for EDSIVO(TM) for the treatment of COL3A1+ vEDS. On the corporate front, we have enhanced our management team with four important senior-level hires across their respective disciplines, including program and alliance management, marketing, and clinical development. I warmly welcome our new team members, who bring deep industry knowledge and tremendous experience, and look forward to their contributions as we position ourselves for growth.”
Q2 2021 and Recent Highlights
– ACER-001 (sodium phenylbutyrate)
— Following completion of a Q2 2021 pre-NDA meeting with the U.S. Food and Drug Administration (FDA), submitted a New Drug Application (NDA) in August 2021 for ACER-001 for the treatment of Urea Cycle Disorders (UCDs)
— Reached agreement with FDA on the Company’s initial Pediatric Study Plan (iPSP) which outlines an approach that addresses the needs of pediatric patients with UCDs
– ACER-801 (osanetant)
— Continued to advance toward an Investigational New Drug Application (IND) submission for the treatment of vasomotor symptoms (VMS)
– EDSIVO(TM) (celiprolol)
— Following completion of a Type B meeting with FDA, in June 2021 Acer announced plans to conduct a pivotal Phase 3, randomized, double-blind, placebo-controlled, decentralized clinical trial for EDSIVO(TM) for patients with COL3A1+ vascular Ehlers-Danlos Syndrome (vEDS), subject to available capital
– The DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) trial is estimated to take approximately 3.5 years to complete, once fully enrolled
– FDA indicated agreement with Acer’s plans to submit a proposed protocol under the IND Special Protocol Assessment (SPA) process with possible breakthrough designation
– Launched www.discoverceliprolol.com as an outreach tool for interested parties
– Hired Tanya Hayden, Vice President of Program and Strategic Alliance Management, in June 2021. During her nearly 20-year tenure at Lonza (formerly Bend Research/Capsugel), Ms. Hayden was responsible for oral drug delivery technologies, clinical and commercial contract manufacturing, operational excellence and client-focused project management
– Hired John Hilton, Vice President of Marketing and Strategic Insights, in July 2021. Mr. Hilton brings over 20 years of biopharmaceutical industry experience including marketing, sales, KOL development, pipeline marketing, and access strategy functions, as well as oversight of launch planning for ten new products in the last ten years
– Hired Terrie Kellmeyer, Ph.D., Vice President of Clinical Development, in August 2021. Dr. Kellmeyer brings to Acer over 23 years of experience in the pharmaceutical industry spanning the areas of Clinical Development, Regulatory Affairs, Medical Writing and Medical Affairs
– Hired Jeffrey Edwards, Ph.D., Vice President of Clinical Sciences, in August 2021. Dr. Edwards brings to Acer over 16 years of pharmaceutical experience in clinical and preclinical studies and support for regulatory submissions
– Ended Q2 2021 with $22.1 million in cash and cash equivalents. Acer believes its cash and cash equivalents available as of June 30, 2021, plus a $10.0 million Second Development Payment conditioned upon FDA accepting an NDA for ACER-001 in a UCD for filing and review per the Collaboration Agreement with Relief Therapeutics, will be sufficient to fund its currently anticipated operating and capital requirements into mid-2022, excluding support for the planned ACER-801 and EDSIVO(TM) clinical trials
– ACER-001 (sodium phenylbutyrate)
— Q4 2021: Based on standard FDA review timelines, Acer expects to receive notification from FDA on the potential acceptance of the NDA for filing within 60 days of submission and subsequent substantive review
— ACER-001 is an investigational product candidate which has not been approved by FDA. There is no guarantee that this product candidate will be accepted for substantive review, or if accepted, receive regulatory authority approval in any territory, or become commercially available for the indications under investigation
– ACER-801 (osanetant)
— Q4 2021: IND submission for the treatment of VMS is anticipated in Q4 2021
— Q1 2022: Phase 2a clinical trial initiation is expected in Q1 2022 designed to evaluate ACER-801’s PK, efficacy and safety in postmenopausal women and to identify the optimal dosing strategy for subsequent efficacy studies in certain cancer patients with induced vasomotor symptoms (iVMS), dependent upon successful IND submission and clearance, and subject to additional capital
– EDSIVO(TM) (celiprolol)
— Q4 2021: Submission of the proposed EDSIVO(TM) pivotal trial protocol and IND, request for breakthrough therapy designation, coordination with FDA on SPA agreement, and beginning to identify COL3A1+ vEDS patients for potential trial participation are anticipated in Q4 2021
— Q1 2022: Initiation of the EDSIVO(TM) DiSCOVER pivotal clinical trial is expected in Q1 2022 subject to successful IND submission and clearance, FDA SPA agreement, and obtaining additional capital required to conduct and complete the trial
– ACER-2820 (emetine)
— Ongoing: With most of the emetine IND-enabling work complete, further advancement of the emetine program for treatment of certain infectious diseases, including COVID-19, is dependent on Acer’s ability to raise non-dilutive capital
Each of the ACER product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, ACER entered into a Collaboration and License Agreement with Relief Therapeutics for the worldwide development and commercialization of ACER-001.
DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for dissemination of this article.
These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.